| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Iyo, H Namba, K Fukushi, H Shinotoh, S Nagatsuka, T Suhara, Y Sudo, K Suzuki, T Iri. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet (London, England). vol 349. issue 9068. 1997-09-15. PMID:9269216. |
measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with alzheimer's disease. |
1997-09-15 |
2023-08-12 |
Not clear |
| M Iyo, H Namba, K Fukushi, H Shinotoh, S Nagatsuka, T Suhara, Y Sudo, K Suzuki, T Iri. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet (London, England). vol 349. issue 9068. 1997-09-15. PMID:9269216. |
acetylcholinesterase activity, a marker for degeneration of the central cholinergic system, has consistently been reported, in necropsy brain studies, to be reduced in the cerebral cortex of patients with alzheimer's disease. |
1997-09-15 |
2023-08-12 |
Not clear |
| H S Ved, M L Koenig, J R Dave, B P Docto. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport. vol 8. issue 4. 1997-07-14. PMID:9141073. |
huperzine a, a potential therapeutic agent for alzheimer's disease, inhibits acetylcholinesterase in primary cultures derived from forebrain, hippocampus, cortex and cerebellum of embryonic rat brain. |
1997-07-14 |
2023-08-12 |
rat |
| Y Mimori, S Nakamura, M Yukaw. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behavioural brain research. vol 83. issue 1-2. 1997-07-09. PMID:9062656. |
abnormalities of acetylcholinesterase in alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. |
1997-07-09 |
2023-08-12 |
human |
| Y Mimori, S Nakamura, M Yukaw. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behavioural brain research. vol 83. issue 1-2. 1997-07-09. PMID:9062656. |
in brains from alzheimer's disease patients, a high activity of acetylcholinesterase (ache) was detected in the senile plaque-rich fraction and its isozyme pattern was mainly type a, containing a collagen-like tail. |
1997-07-09 |
2023-08-12 |
human |
| N C Inestrosa, A Alvarez, F Calderó. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments. Molecular psychiatry. vol 1. issue 5. 1997-06-09. PMID:9154226. |
acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into alzheimer's filaments. |
1997-06-09 |
2023-08-12 |
Not clear |
| J Y Lehtonen, M Rytömaa, P K Kinnune. Characteristics of the binding of tacrine to acidic phospholipids. Biophysical journal. vol 70. issue 5. 1997-06-05. PMID:9172742. |
tacrine (1,2,3,4-tetrahydro-9-acridinamine monohydrate) is an inhibitor of acetylcholinesterase currently used in the treatment of the symptoms of alzheimer's disease. |
1997-06-05 |
2023-08-12 |
Not clear |
| R Schliebs, A Liebmann, S K Bhattacharya, A Kumar, S Ghosal, V Big. Systemic administration of defined extracts from Withania somnifera (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochemistry international. vol 30. issue 2. 1997-04-17. PMID:9017665. |
although some promising results have been achieved by acetylcholinesterase inhibitors, an effective therapeutic intervention in alzheimer's disease still remains an important goal. |
1997-04-17 |
2023-08-12 |
rat |
| W P McNally, W F Pool, M W Sinz, P Dehart, D F Ortwine, C C Huang, T Chang, T F Wool. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue. Drug metabolism and disposition: the biological fate of chemicals. vol 24. issue 6. 1997-03-18. PMID:8781777. |
tacrine [1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate (tha), cognex] is a potent acetylcholinesterase inhibitor recently approved for treatment of mild-to-moderate alzheimer's disease. |
1997-03-18 |
2023-08-12 |
rat |
| C P Smith, G M Bores, W Petko, M Li, D E Selk, D K Rush, F Camacho, J T Winslow, R Fishkin, D M Cunningham, K M Brooks, J Roehr, H B Hartman, L Davis, H M Varga. Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. The Journal of pharmacology and experimental therapeutics. vol 280. issue 2. 1997-03-17. PMID:9023283. |
pharmacological activity and safety profile of p10358, a novel, orally active acetylcholinesterase inhibitor for alzheimer's disease. |
1997-03-17 |
2023-08-12 |
mouse |
| Z X She. The significance of the activity of CSF cholinesterases in dementias. Medical hypotheses. vol 47. issue 5. 1997-03-07. PMID:8951800. |
this article reviews the significance of changes in the level of cerebrospinal fluid acetylcholinesterase or cholinesterase in patients with alzheimer's disease or other dementias. |
1997-03-07 |
2023-08-12 |
Not clear |
| Z X She. The significance of the activity of CSF cholinesterases in dementias. Medical hypotheses. vol 47. issue 5. 1997-03-07. PMID:8951800. |
low acetylcholinesterase or cholinesterase levels presenting in cerebrospinal fluid of a demented individual may confirm the clinical diagnosis of alzheimer's disease or other organic dementia. |
1997-03-07 |
2023-08-12 |
Not clear |
| S L Rogers, L T Friedhof. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia (Basel, Switzerland). vol 7. issue 6. 1997-02-18. PMID:8915035. |
this study evaluated the efficacy and safety of donepezil in patients with mild to moderately severe alzheimer's disease, and examined the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase (ache) activity and clinical response. |
1997-02-18 |
2023-08-12 |
Not clear |
| R E Becker, J A Colliver, S J Markwell, P L Moriearty, L K Unni, S Vicar. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer disease and associated disorders. vol 10. issue 3. 1997-01-16. PMID:8876775. |
double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for alzheimer disease. |
1997-01-16 |
2023-08-12 |
Not clear |
| B Fulton, P Benfiel. Galanthamine. Drugs & aging. vol 9. issue 1. 1996-12-06. PMID:8818586. |
galanthamine is a selective acetylcholinesterase inhibitor which has shown potential for the treatment of alzheimer's disease. |
1996-12-06 |
2023-08-12 |
human |
| C Geula, M M Mesula. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cerebral cortex (New York, N.Y. : 1991). vol 6. issue 2. 1996-11-27. PMID:8670647. |
the loss of cortical cholinergic fibers in alzheimer's disease was investigated using choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. |
1996-11-27 |
2023-08-12 |
Not clear |
| D Arsland, K Laak. [Should Alzheimer disease be treated with tacrine? Review of the literature]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. vol 116. issue 23. 1996-11-26. PMID:8928167. |
the authors describe the rationale for use of the acetylcholinesterase inhibitor, tacrine, in alzheimer's disease and critically review the controlled clinical trials using this drug. |
1996-11-26 |
2023-08-12 |
Not clear |
| H Soininen, M Lehtovirta, S Helisalmi, K Linnaranta, O Heinonen, P Riekkine. Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein epsilon4 allele. Neuroreport. vol 6. issue 18. 1996-10-24. PMID:8741753. |
increased acetylcholinesterase activity in the csf of alzheimer patients carrying apolipoprotein epsilon4 allele. |
1996-10-24 |
2023-08-12 |
Not clear |
| H Soininen, M Lehtovirta, S Helisalmi, K Linnaranta, O Heinonen, P Riekkine. Increased acetylcholinesterase activity in the CSF of Alzheimer patients carrying apolipoprotein epsilon4 allele. Neuroreport. vol 6. issue 18. 1996-10-24. PMID:8741753. |
we measured csf acetylcholinesterase (ache) activity in 57 alzheimer's disease (ad) patients with different apolipoprotein e (apoe) genotypes at the early stage of the disease, and in 11 non-demented controls. |
1996-10-24 |
2023-08-12 |
Not clear |
| C Llanes, R G Collman, R Hrin, D L Kolso. Acetylcholinesterase expression in NTera 2 human neuronal cells: a model for developmental expression in the nervous system. Journal of neuroscience research. vol 42. issue 6. 1996-10-22. PMID:8847741. |
acetylcholinesterase (ache; ec 3.1.1.7) is expressed in the central nervous system in multiple molecular forms that may subserve multiple functions and may be selectively lost in neurodegenerative illnesses such as alzheimer's disease. |
1996-10-22 |
2023-08-12 |
human |